On July 28, KEYMED BIO-B declined 5.59% in regular trading, trading at 77.8 HKD/share, with turnover of HKD 476 million.

On the news front, the company announced that CMG901 (AZD0901), a CLDN18.2-targeting antibody-drug conjugate co-developed with AstraZeneca, achieved positive topline results in the global Phase 3 trial CLARITY-Gastric01. The trial demonstrated statistically significant and clinically meaningful overall survival improvement in second- or later-line CLDN18.2-positive advanced gastric cancer patients compared with investigator's choice of treatment. The safety profile was consistent with previous studies, with no new safety signals identified. The company estimates peak annual sales of USD 3 billion to USD 5 billion for the drug candidate.

Despite the positive clinical readout, shares exhibited a classic sell-the-news pattern, suggesting the market had already priced in the favorable outcome ahead of the data release. Within the Biotechnology sector, LEADS BIOLABS-B fell 7.67%, BEIGENE fell 2.20%, AKESO fell 2.74%, 3SBIO fell 0.12%, while INNOVENT BIO rose 0.56%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)